- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute lymphoblastic leukaemia (ALL)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Inotuzumab Ozogamicin – March 2026
Powder for I.V. infusion 1 mg
Last updated
11 March 2026